Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
- 17 March 2014
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 4 (4) , 156-169
Abstract
Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on their clinic effectiveness. These drugs appear to exert their psychedelic effects through their agonist or partial agonist activity at the serotonergic 5-HT2Areceptor, though they also have affinity for other metabotropic serotonin receptors. Hallucinogen binding affects a wide range of intracellular signalling pathways, the precise nature of which remains incompletely understood. They alter the serotonergic tone of brainstem raphe nuclei that project through the brain; they interact with receptors in the prefrontal cortex altering connectivity patterns and intracellular functioning; and they disrupt inhibitory control of sensory input via the thalamus to the cortex. The serotonergic system has long been implicated in anxiety and depressive disorders, and is a major target of most existing antidepressants. Classical hallucinogens alter the functioning of this system, but not in the same way current medications do: whilst there are identified receptors and neurotransmitter pathways through which hallucinogens could therein produce therapeutic effects, the neurobiology of this remains speculative at this time. There is currently an extremely limited but growing literature on hallucinogen safety and clinical application. The drugs appear well tolerated by healthy controls and clinical populations, and the rapid tolerance to repeated administration might reduce the possibility of dependency. Clinical trials reported over the past decade have generally shown positive therapeutic potential, but they are notably few in number. Legislative policy has had a freezing effect on evaluation of these compounds, a better understanding of which might improve our knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies.Keywords
This publication has 78 references indexed in Scilit:
- Mechanisms Underlying Auditory Hallucinations—Understanding Perception without StimulusBrain Sciences, 2013
- Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal NeurogenesisNeuropsychopharmacology, 2011
- Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsNeuroscience Letters, 2011
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review.Journal of Consulting and Clinical Psychology, 2010
- 5-HT1A receptor function in major depressive disorderProgress in Neurobiology, 2009
- The molecular neurobiology of depressionNature, 2008
- Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and ImplicationsBiological Psychiatry, 2008
- From inflammation to sickness and depression: when the immune system subjugates the brainNature Reviews Neuroscience, 2008
- Cytokine Production and Treatment Response in Major Depressive DisorderNeuropsychopharmacology, 2000